News Image

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Provided By GlobeNewswire

Last update: Sep 29, 2025

Abivax Announces Acceptance of Additional
Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Read more at globenewswire.com

ABIVAX SA-ADR

NASDAQ:ABVX (10/9/2025, 7:53:52 PM)

After market: 91.99 +1.38 (+1.52%)

90.61

+4.1 (+4.74%)



Find more stocks in the Stock Screener

Follow ChartMill for more